Literature DB >> 30186889

Successful Treatment of a Renal Abscess Caused by Mycobacterium chelonae: A Case Report.

Elizabeth Verghese1, Ahmad Jabri1, Richard R Watkins2,3.   

Abstract

Entities:  

Year:  2018        PMID: 30186889      PMCID: PMC6119465          DOI: 10.1093/ofid/ofy196

Source DB:  PubMed          Journal:  Open Forum Infect Dis        ISSN: 2328-8957            Impact factor:   3.835


× No keyword cloud information.

CASE

A 46-year-old woman presented to the emergency department with 2 weeks of nausea, vomiting, and abdominal pain. She denied fever, chills, or urinary symptoms, although her urine was darker than usual. Physical examination showed normal vital signs and tenderness over her right flank. Laboratory analysis revealed a leukocytosis (normal range) of 16.8 (3.98–10.04) thou/cmm with a segmented neutrophil percentage of 13.20 (1.56–6.13) thou/cmm and a creatinine of 0.48 (0.51–0.95) mg/dL. A computerized tomography (CT) scan of the abdomen and pelvis with intravenous contrast showed a 3.7 cm × 4.1 cm × 3.9 cm fluid collection suspicious for an abscess (Figure 1). The initial urinalysis with microscopy was unremarkable, and the urine culture was negative.
Figure 1.

Initial computed tomography scan showing right renal abscess.

Initial computed tomography scan showing right renal abscess. The patient was admitted to the hospital, and a CT-guided aspiration of the right renal mass was performed. The pathology was negative for malignancy, and aerobic and anaerobic cultures were negative. She was discharged home on oral ciprofloxacin. She was readmitted for recurrent abdominal pain 5 days later. An infectious disease consultant ordered a urine acid-fast bacillus (AFB) smear and culture. The AFB smear was positive, and Mycobacterium chelonae grew in the AFB culture 5 days later. The antimicrobial sensitivities of the M. chelonae are reported in Table 1.
Table 1.

 Antibiotic Sensitivities for

AntibioticMinimum Inhibitory Concentration, mg/L
Clarithromycin<2 sensitive
Amikacin8 sensitive
Cefoxitin>128 resistant
Doxycycline<0.12 sensitive
Imipenem32 resistant
Tobramycin<1 sensitive

aAntimicrobial susceptibility of the clinical isolates was determined using the disc dilution method, and the results were interpreted according to the breakpoints recommended by the Clinical and Laboratory Standards Institute.

Antibiotic Sensitivities for aAntimicrobial susceptibility of the clinical isolates was determined using the disc dilution method, and the results were interpreted according to the breakpoints recommended by the Clinical and Laboratory Standards Institute. The patient was started on parenteral tobramycin 5 mg/kg daily and oral doxycycline 100 mg twice daily. A baseline audiology test showed normal hearing. After 18 days, the tobramycin was discontinued due to tinnitus and acute kidney injury (creatinine 2.8 mg/dL). A repeat CT scan of the abdomen and pelvis done after 3 months of therapy demonstrated a complete resolution of the renal abscess (Figure 2). Her tinnitus and acute kidney injury resolved after discontinuation of the tobramycin, and she completed a 4-month course of doxycycline alone. A lung biopsy revealed adenocarcinoma of the left lung. An AFB smear and culture, along with routine bacterial cultures from the biopsy, were negative.
Figure 2.

Follow-up computed tomography image showing resolution of the Mycobacterium chelonae right renal abscess.

Follow-up computed tomography image showing resolution of the Mycobacterium chelonae right renal abscess. The patient was seen in the office 2 months after completing the doxycycline, and repeat laboratory testing and audiology testing were normal (creatinine 0.9 mg/dL). She underwent chemotherapy for the adenocarcinoma and is currently in remission, with no signs of recurrent M. chelonae infection.

DISCUSSION

Nontuberculosis mycobacteria are rare causes of urinary infections [1, 2]. M. chelonae usually causes infections in immunocompromised patients, including those with malignancy and organ transplants [3-6]. Thus, our patient’s malignancy, which was undiagnosed at her initial presentation, may have predisposed her to develop the renal abscess from M. chelonae. Antibiotics with activity against M. chelonae include tobramycin, clarithromycin, linezolid, imipenem, amikacin, clofazimine, doxycycline, tigecycline, and ciprofloxacin. Tobramycin is more active in vitro than amikacin, has been shown to reach therapeutic concentrations in the kidney [7], and can be used to treat pyelonephritis [8]. The treatment guidelines for M. chelonae recommend a minimum of 4 months of combination therapy to achieve a high likelihood of cure [9]. Macrolides (eg, clarithromycin or azithromycin) are the drugs of choice for disseminated M. chelonae infection and are widely used in combination regimens [10]. The choice to use tobramycin and doxycycline was based on several factors. The patient claimed that azithromycin previously caused severe nausea. Antinausea medication was offered, but she still declined and also refused clarithromycin. Therefore, it was decided to prescribe parenteral tobramycin to achieve high drug levels in the kidney, along with doxycycline. After the tobramycin was discontinued, options for another antibiotic were limited. The patient wanted to avoid any additional risk of toxicities and preferred to continue just the doxycycline. Surgery is generally indicated in cases of abscess formation or when antibiotic therapy is difficult [9]. Obtaining a urological opinion for possible surgical excision of the abscess was offered, but she declined this as well. As only approximately 20% of strains of M. chelonae are susceptible to doxycycline [11], the fact that our patient had a favorable outcome with doxycycline for most of her clinical course seems noteworthy. Indeed, there is no compelling rationale or evidence that doxycycline has any special properties that would make it especially effective in our case. This is the first reported case of a renal abscess due to M. chelonae. Usually M. chelonae is treated with combination antibiotic therapy, including a macrolide. Our patient completed slightly more than 2 weeks of doxycycline and tobramycin dual therapy, followed by nearly 4 months of doxycycline monotherapy, achieving a clinical cure of the renal abscess based on symptom resolution and follow-up radiological imaging.
  11 in total

1.  Renal abscess due to Mycobacterium avium complex in a human immunodeficiency virus-positive patient.

Authors:  Robert Colebunders; Ilse Kint; Ivan Bastian; Eva Mortelmans; Werner Jacobs; Eric Van Marck
Journal:  Int J Infect Dis       Date:  2002-09       Impact factor: 3.623

Review 2.  The aminoglycosides.

Authors:  P Duff
Journal:  Obstet Gynecol Clin North Am       Date:  1992-09       Impact factor: 2.844

Review 3.  An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases.

Authors:  David E Griffith; Timothy Aksamit; Barbara A Brown-Elliott; Antonino Catanzaro; Charles Daley; Fred Gordin; Steven M Holland; Robert Horsburgh; Gwen Huitt; Michael F Iademarco; Michael Iseman; Kenneth Olivier; Stephen Ruoss; C Fordham von Reyn; Richard J Wallace; Kevin Winthrop
Journal:  Am J Respir Crit Care Med       Date:  2007-02-15       Impact factor: 21.405

Review 4.  [A case of a patient with post-operative empyema due to Mycobacterium chelonae].

Authors:  N Takemoto; R Kohiyama; J Tsuboi; K Sasaki; I Sakurabayashi; M Miyata
Journal:  Kyobu Geka       Date:  1996-04

5.  Disseminated Mycobacterium chelonae infection in a patient receiving an epidermal growth factor receptor inhibitor for advanced head and neck cancer.

Authors:  Charles M Bark; Rana S Traboulsi; Kord Honda; Autumn M Starnes; Michael R Jacobs; Benigno Rodriguez
Journal:  J Clin Microbiol       Date:  2011-10-26       Impact factor: 5.948

6.  Comparison of the in vitro activity of the glycylcycline tigecycline (formerly GAR-936) with those of tetracycline, minocycline, and doxycycline against isolates of nontuberculous mycobacteria.

Authors:  Richard J Wallace; Barbara A Brown-Elliott; Christopher J Crist; Linda Mann; Rebecca W Wilson
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

7.  Clinical trial of clarithromycin for cutaneous (disseminated) infection due to Mycobacterium chelonae.

Authors:  R J Wallace; D Tanner; P J Brennan; B A Brown
Journal:  Ann Intern Med       Date:  1993-09-15       Impact factor: 25.391

Review 8.  Mycobacterium chelonae complex bacteremia from a post-renal transplant patient: case report and literature review.

Authors:  Ali Mohammed Somily; Awadh Raheel Al-Anazi; Hanan Ahmed Babay; Abdulkarim Ibraheem Al-Aska; Mugbil Ahmed Al-Hedaithy; Waleed Khalid Al-Hamoudi; Ahmad Amer Al Boukai; Mohammed Sarwar Sabri; Sahar Isa AlThawadi; Abdelmageed Mohamed Kambal
Journal:  Jpn J Infect Dis       Date:  2010-01       Impact factor: 1.362

9.  Disseminated Mycobacterium chelonae infection in a patient with T-cell lymphoma.

Authors:  Lena van der Wekken; Jacobine Herbrink; Dominic Snijders; Martine Chamuleau; Anita Griffioen
Journal:  Hematol Oncol Stem Cell Ther       Date:  2016-05-11

10.  Efficacy and safety of once daily versus intermittent dosing of tobramycin in rabbits with acute pyelonephritis.

Authors:  L Herscovici; G Grise; C Thauvin; J F Lemeland; J P Fillastre
Journal:  Scand J Infect Dis       Date:  1988
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.